The co-administration of mesna with Dox reduced plasma levels of TNF-α, TNFR1 and TNFR2 compared to saline for patients with high baseline values receiving Dox for breast cancer and NHL. The gene discussed is TNFRSF1A; the disease is non-Hodgkin lymphoma.